Showing 1351-1360 of 2050 results for "".
- CooperVision Launches Major US Myopia Control Advocacy and Education Campaignhttps://modernod.com/news/coopervision-launches-major-us-myopia-control-advocacy-and-education-campaign/2481474/CooperVision has unveiled a multifaceted consumer and professional marketing campaign to protect children’s vision and advance myopia control education in the United States to kick off Vision Expo East 2023. The “Make Children’s Sight Your Fight” initiative is rooted in ne
- Bausch + Lomb Receives 510(k) Clearance from FDA for Biotrue Hydration Boost Contact Lens Rehydrating Dropshttps://modernod.com/news/bausch-lomb-receives-510k-clearance-from-fda-for-biotrue-hydration-boost-contact-lens-rehydrating-drops/2481290/Bausch + Lomb announced that it has received 510(k) clearance from the FDA for Biotrue Hydration Boost Contact Lens Rehydrating drops, a preservative-free multi-dose rehydrating drop for use with soft and rigid gas permeable contact lenses. “We ar
- Nidek Launches the NT-1p Non-Contact Tono/Pachymeterhttps://modernod.com/news/nidek-launches-the-nt-1p-non-contact-tonopachymeter/2481241/Nidek announced the launch of the NT-1p Non-Contact Tono/Pachymeter. The NT-1p is an innovative device that fully automates reliable non-contact tonometry and pachymetry. By placing the chin on the chinrest, the NT-1p automatically detects the position of the eyes and begins measurement without p
- CooperVision Adds SynergEyes to Expand Specialty Contact Lens Adoption in North Americahttps://modernod.com/news/coopervision-adds-synergeyes-to-expand-specialty-contact-lens-adoption-in-north-america/2481220/Deepening its commitment to expand specialty contact lens adoption in North America and worldwide, CooperVision has added
- Johnson & Johnson Vision Reveals New Data on Blue-Violet Light Filtering Technology in Acuvue Oasys Max 1-Day Contact Lenseshttps://modernod.com/news/johnson-johnson-vision-reveals-new-data-on-blue-violet-light-filtering-technology-in-acuvue-oasys-max-1-day-contact-lenses/2481196/Johnson & Johnson Vision Care will present new data on the positive effects of wearing blue-violet light filtering contact lenses at the 2022 American Academy of Optometry (AAO) annual meeting in San Diego, October 26-29. "As a result of our increasingly digital
- Johnson & Johnson Vision to Launch Acuvue Oasys Max 1-Day Contact Lenses in Several Marketshttps://modernod.com/news/johnson-johnson-vision-to-launch-acuvue-oasys-max-1-day-contact-lenses-in-several-markets/2480914/Johnson & Johnson Vision announced it has received FDA clearance, Health Canada approval, and completed CE Mark activities for its latest contact lens, Acuvue Oasys Max 1-Day and Acuvue Oasys Max 1-Day Multifocal. The announcement comes during the 125th Annual AOA Congress and 54th<
- AMA: Health Insurance Industry Continues to Falter on Prior Authorization Reformhttps://modernod.com/news/ama-health-insurance-industry-continues-to-falter-on-prior-authorization-reform/2480880/Despite mounting evidence that insurer-imposed authorizations for drugs and medical services can be a hazardous and burdensome administrative obstacle to patient-centered care, the health insurer industry continues to show apathetic or ineffectual follow-through on mutually accepted reforms, acco
- Belkin Vision's Automated, Non-Contact Glaucoma Laser Treatment Receives CE Markhttps://modernod.com/news/belkin-visions-eagle-receives-ce-mark-under-mdr/2480859/Israel-based Belkin Vision announced that it has received CE Mark for its Eagle device, making it the first automated, non-contact glaucoma laser treatment available within Europe. The CE Mark was granted under Medical Device Regulation (MDR) from its notified body DEKRA.
- Apellis' Pegcetacoplan Showed Continuous Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-pegcetacoplan-showed-continuous-and-clinically-meaningful-effects-at-month-18-in-phase-3-derby-and-oaks-studies-for-geographic-atrophy-ga/2480701/Apellis Pharmaceuticals announced longer-term data from the phase 3 DERBY and OAKS studies, which showed that intravitreal pegcetacoplan, an investigational, targeted C3 therapy, continued to reduce geographic atrophy (GA) lesion growth and demonstrate a favorable safety profile at month 18 for t
- Johnson & Johnson Vision Receives FDA Approval for First Drug-Eluting Contact Lens—Acuvue Theravision with Ketotifenhttps://modernod.com/news/johnson-johnson-vision-receives-fda-approval-for-first-drug-eluting-contact-lens-acuvue-theravision-with-ketotifen/2480676/Johnson & Johnson Vision Care announced that the FDA has approved Acuvue Theravision with Ketotifen (etafilcon A drug-eluting contact lens with ketotifen), the first drug-eluting contact lens. Each lens contains 19 mcg ketotifen, an antihistamine. Acuv